miRagen Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference

BOULDER, Colo.–(BUSINESS WIRE)– miRagen Therapeutics, Inc., a clinical-stage biopharmaceutical company
developing innovative microRNA-based therapeutics, today announced its
participation in the 2016 Wedbush PacGrow Healthcare Conference.

Conference Details:

The 2016 Wedbush PacGrow Healthcare Conference

On August 16, 2016, President and CEO William S. Marshall, Ph.D., will
present a corporate overview at 12:45pm EDT. The conference is being
held at Le Parker Meridien in New York City.

About miRagen Therapeutics, Inc.

miRagen Therapeutics, Inc., is a clinical-stage biopharmaceutical
company focused on the discovery and development of innovative microRNA
(miRNA)-targeting therapies in disease areas of high unmet medical need.
The Company’s lead product candidate, MRG-106, a synthetic microRNA
antagonist (LNA antimiR) of microRNA-155 is currently being studied in a
Phase 1 clinical trial in patients suffering from cutaneous T-cell
lymphoma (CTCL) of the mycosis fungoides (MF) sub-type. miRagen is also
conducting a Phase 1 clinical trial of MRG-201, the Company’s lead
anti-fibrosis product candidate and a synthetic microRNA mimic (promiR)
to microRNA-29b, in human volunteers. The Company seeks to leverage
in-house expertise in miRNA biology, oligonucleotide chemistry, and drug
development to evaluate and advance promising technologies and
high-potential product candidates for its own pipeline and in
conjunction with strategic collaborators.

About MRG-106 and microRNA-155

MRG-106 is an antimiR (antagonist) of microRNA-155. In hematological
malignancy microRNA-155 has key roles in the differentiation, function
and proliferation of blood and lymph cells. Therapeutic inhibition
(antagonism) of microRNA-155 in lymphoma cells restores normal function
and reduces the aberrant cell proliferation that is characteristic of
cancerous cells.

About MRG-201 and microRNA-29

MRG-201 is a promiR (agonist) to microRNA-29b. The microRNA-29 family is
a well-established negative regulator of a wide variety of genes
important in extracellular matrix deposition. The expression of the
three family members is consistently down-regulated in a number of
pathological fibrotic conditions, including cardiac, renal, hepatic, and
pulmonary fibrosis, as well as systemic sclerosis. Numerous studies in
cell-culture and genetic replacement in rodents have also demonstrated
the potential of miR-29 normalization to correct many drivers of
pathological fibrosis.

For more information, please visit www.miragenrx.com.

For information on clinical trials, please visit www.clinicaltrials.gov.

Safe Harbor Statement

This press release contains “forward-looking statements” for purposes
of the safe harbor provided by the Private Securities Litigation Reform
Act of 1995. These statements include, but are not limited to,
statements regarding the role of microRNAs in disease processes and as
potential drug products, the potential for MRG-106, MRG-107 and MRG-201
to target diseases, the adequacy of the Company’s capital to support its
future operations and the Company’s ability to successfully initiate and
complete clinical trials. Such statements are based on management’s
current expectations and involve risks and uncertainties. Actual results
and performance could differ materially from those projected in the
forward-looking statements as a result of many factors, including,
without limitation, results of earlier studies and trials may not be
predictive of future clinical trial results, the protection and market
exclusivity provided by the Company’s intellectual property; risks
related to the drug discovery and the regulatory approval process, the
risks and uncertainties associated with: the Company’s financial
resources and whether they will be sufficient to meet the Company’s
business objectives and operational requirements; and, the impact of
competitive products and technological changes. The Company disclaims
any intent or obligation to update these forward-looking statements.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160811005143/en/